Drug Patents owned by Axsome Malta

1. List of Sunosi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11439597 AXSOME MALTA Formulations of (R)-2-amino-3-phenylpropyl carbamate
Sep, 2037

(14 years from now)

US11560354 AXSOME MALTA Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof
Mar, 2039

(15 years from now)

US11160779 AXSOME MALTA Methods of providing solriamfetol therapy to subjects with impaired renal function
Mar, 2040

(16 years from now)

Do you want to check out SUNOSI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2026

Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient

NCE-1 date: 2023-06-18

Market Authorisation Date: 17 June, 2019

Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropa...

Dosage: TABLET;ORAL

More Information on Dosage

SUNOSI family patents

6

United States

1

Korea, Republic of

1

China

1

Russia

1

Philippines

1

Chile

1

Israel

1

Canada

1

Singapore

1

Mexico

1

Japan

1

Australia

1

Denmark

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in